[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Centre Hospitalier Universitaire de la Guadeloupe\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":600},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,23,0,[8,44,79,107,134,159,180,205,230,256,279,301,330,357,380,406,428,453,475,501,524,549,574],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100640858","analysis-of-chlordecone-tissue-concentrations-in-patients-treated-for-thyroid-surgery-at-guadeloupe-university-hospital-100640858",false,"NCT07611994","Analysis of Chlordecone Tissue Concentrations in Patients Treated for Thyroid Surgery at Guadeloupe University Hospital","COTICHLO","Inclusion Criteria:\n\n* adult patients hospitalized at the Guadeloupe University Hospital for surgical treatment of thyroid pathology\n* person affiliated to or beneficiaries of a social security system\n* person with free, informed, and written consent signed by the participant and the investigator\n\nExclusion Criteria:\n\n* patients subject to a judicial safeguard measure,\n* patient under 18 years old\n* patient without signed consent\n* current pregnancy at the time of inclusion","ALL","18 Years",{"count":19,"type":20},69,"ESTIMATED","INTERVENTIONAL",[23],"NA","Chlordecone, an organochlorine pesticide used in the French Caribbean for several decades, is recognized as an endocrine disruptor. Accumulation in thyroid tissue may be modeled using several factors, including blood chlordecone levels, environmental exposure associated with place of residence, and dietary habits.",[26],"Thyroid and Parathyroid Surgery",[28,29,30],"chlordecone","thyroid nodes","thyroid disruptor","NOT_YET_RECRUITING","2026-05-28",{"date":34,"type":35},"2026-06-01","ACTUAL",{"date":37,"type":20},"2026-07-01",{"date":39,"type":20},"2027-11-01",{"name":41,"class":42},"Centre Hospitalier Universitaire de la Guadeloupe","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":63,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":43},"100639957","specificities-of-atypical-non-autoimmune-diabetes-anaid-in-the-french-west-indies-100639957","NCT07576374","Specificities of Atypical Non AutoImmune Diabetes (ANAID) in the French West Indies","Epidemiological, Clinical, Biological and Genetic Specificities of Atypical Non-AutoImmune Diabetes (ANAID) in the French West Indies","DiAGeNA","Inclusion Criteria:\n\nPhenotypic criteria :\n\nSubjects from Indian or African Ancestry self-declared\n\nAge criteria at diagnosis:\n\nEarly onset of diabetes: patient aged between 18 and 47 years at the time of diagnosis of diabetes Clinical criteria: at least 2 criteria Labeled type 2 diabetic\n\nPatient hospitalized for:\n\nKetoacid decompensation Significant weight loss (more than 10% in less than 6 months) without obvious etiology Lipodystrophic \u002F lipoatrophic appearance Presence of an associated myopathy or deafness Presence of early inaugural nephropathy or within 3 years after diagnosis Presence of early inaugural heart disease or within 3 years after diagnosis Poor response to non-insulin treatments despite good adherence\n\nBiological criteria:\n\nAbsent T1D autoantibodies:\n\nAnti-islet antibodies (ICA) Anti-IA2 antibodies Anti-insulin antibodies Anti-ZnT8 antibodies Anti-GAD antibodies\n\nOther criteria:\n\nInformed consent signed by the patient\n\nExclusion Criteria:\n\nType 1 diabetes (T1D) Presence of T1D antibodies Secondary diabetes (pancreas diseases, endocrine diseases, drug intake, infection) Other associated autoimmune pathologies Pregnancy Refusal to participate","47 Years",{"count":54,"type":20},118,"OBSERVATIONAL","Genetics variants could be involved in atypical non-autoimmune diabetes revealed by ketoacidosis. The objective of this research will be to determine the relationships between the genetic variants already described in known monogenic diabetes or identified as involved in glucose metabolism and its regulation, in insulin signaling pathways or in insulin secretion itself in subjects of African and Indian ancestry with atypical forms of non autoimmune diabetes.",[58,59,60,61,62],"Metabolic Diseases","Diabetes Mellitus (Type 2)","Genetic Variation","Genetic Profile","Glucose Metabolism Disorders",[64,65,66,67,68,69,70],"Genetic diagnosis","Monogenic diabetes","Exome sequencing","Pathogenic variant","Ketoacidosis","Afro-Caribbean","African and Indian ancestry","2026-05-04",{"date":73,"type":35},"2026-05-08",{"date":75,"type":20},"2026-06",{"date":77,"type":20},"2029-09",{"name":41,"class":42},{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":89,"conditions":90,"keywords":92,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},"100618377","study-of-pnpla3-genetic-polymorphisms-in-patients-with-non-alcoholic-fatty-liver-disease-in-an-ultramarine-population-adipodromexpo-100618377","NCT07330830","Study of PNPLA3 Genetic Polymorphisms in Patients With Non-Alcoholic Fatty Liver Disease in an Ultramarine Population (AdipoDROMExpo)","Study of PNPLA3 Genetic Polymorphisms in Patients With Non-Alcoholic Fatty Liver Disease in an Ultramarine Population","AdipoDROMExpo","IInclusion Criteria\n\n-Adult patients (≥18 years old) seen in consultation or hospitalized in the Hepato-Gastroenterology Departments of the University Hospitals of Guadeloupe, French Guiana, and Réunion Island, with a diagnosis of MASLD.\n\nMASLD is defined as evidence of hepatic steatosis associated with overweight\u002Fobesity, type 2 diabetes, or metabolic syndrome according to ATP III (2005) criteria.\n\n* Patients affiliated with, or beneficiaries of, a social security scheme.\n* Free, informed, and written consent obtained from the participant and signed by both the participant and the investigator (no later than the day of inclusion and prior to any procedure required by the study).\n\nExclusion Criteria:\n\n* Patients under 18 years of age.\n* Patients unable to provide informed consent; so-called vulnerable populations (individuals under guardianship, judicial protection, etc.).\n* Presence of another cause of chronic liver disease, including:\n\nViral hepatitis (B, C, or E)\n\nPrimary biliary cholangitis or primary sclerosing cholangitis\n\nAutoimmune hepatitis\n\nWilson's disease\n\nHemochromatosis\n\nAlpha-1 antitrypsin deficiency\n\nAlcoholic liver disease, or daily alcohol consumption \\>30 g\u002Fday for men or \\>20 g\u002Fday for women\n\n-Pregnant women.",{"count":88,"type":20},600,"Metabolic Dysfunction Associated Liver Disease (MASLD) is associated with metabolic syndrome, and PNPLA3 variants are known to be implicated in intrahepatic lipid accumulation and linked to lipotoxicity. Analysis of PNPLA3 polymorphisms in an overseas territories population of MASLD would be interesting to describe their profile susceptibility to develop Metabolic dysfunction associated steatohepatitis (MASH).",[91],"MASLD\u002FMASH (Metabolic Dysfunction-Associated Steatotic Liver Disease \u002F Metabolic Dysfunction-Associated Steatohepatitis)",[93,94,95,96],"MASLD","MASH","PNPLA3","genetic polymorphism","RECRUITING","2026-01-05",{"date":100,"type":35},"2026-01-09",{"date":102,"type":35},"2025-11-26",{"date":104,"type":20},"2027-11-28",{"name":41,"class":42},3,{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":114,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":21,"phases":117,"briefSummary":118,"conditions":119,"keywords":121,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":127,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":133},"100618375","study-of-the-double-polymorphism-thr-555ile-and-glu568pro-of-the-corin-gene-as-a-risk-factor-for-arterial-hypertension-in-a-population-of-african-descent-in-guadeloupe-100618375","NCT07330804","STUDY OF THE DOUBLE POLYMORPHISM (THR 555ILE) AND (GLU568PRO) OF THE CORIN GENE AS A RISK FACTOR FOR ARTERIAL HYPERTENSION IN A POPULATION OF AFRICAN DESCENT IN GUADELOUPE","HTAG-CORIN","Inclusion Criteria:\n\nCase inclusion criteria\n\n* Persons affiliated with or benefiting from a social security plan;\n* Over 18 years of age;\n* Considering themselves to be of Afro-Caribbean descent;\n* Having given their free, informed, written and signed consent (at the latest on the day of inclusion and before any examination required by the research);\n* Treated for hypertension or presenting with hypertension according to recommendations: elevated blood pressure (BP), including systolic blood pressure (SBP) ≥140 mmHg and\u002For diastolic blood pressure (DBP) ≥ 90 mmHg measured in the physician's office and confirmed over several visits on the day of inclusion or diagnosis made by ABPM or self-measurement.\n\nControl inclusion criteria:\n\n* Individuals affiliated with or benefiting from a social security plan;\n* Over 18 years of age;\n* Patients who consider themselves of Afro-Caribbean origin, of the same sex as the cases and ± 5 years of age, not treated for hypertension and not presenting with hypertension according to the HAS recommendations on the day of the inclusion visit. Controls will be recruited by the same GPs who included a person with hypertension, consulting for any other symptom\n* Having given their free, informed, written and signed consent (at the latest on the day of inclusion and before any examination required by the research);\n\nExclusion Criteria:\n\n* Minors; Pregnant or breastfeeding women; Protected persons, or persons under court protection; Refusal to participate. Patients unable to come to the laboratory",true,{"count":116,"type":20},370,[23],"Cardiovascular disease (CVD) mortality is the leading cause of death in high-income countries (particularly the United States), accounting for 23.1% of all deaths It has been established over several decades that hypertension disproportionately affects African Americans, compared with Americans of European descent:Hypertension occurs more often, at an earlier age , with greater severity , and is associated with an approximately 3-fold higher probability of death .There is also poorer control of hypertension despit e similar treatment In African Americans, CVD morbidity and mortality are compounded by the higher prevalence of T2DM, obesity, CKD, stroke, and heart failure . Despite advances in the identification of risk factors and the availability of effective treatment in hypertension, CVD disparities, persist among African Americans and are expected to increase in the future, particularly in younger age groups. Although various environmental and social factors certainly contribute to these disparities, a genetic basis, involving numerous \"candidate\" genes, is most often asserted in the literature . One of these is the Corin gene (Pan et al, 2002) which codes for the Corin protein.The latter plays a pivotal role in cardiometabolic pathophysiology through its role in the activation of natriuretic peptides .Natriuretic peptides (ANP and BNP) have a major role in the regulation of blood pressure through their vasodilatory and diuretic action. They have a lusotropic action, inhibit the renin angiotensin system, and are involved in energy metabolism (increased lipolysis and insulin secretion). They also have an anti-fibrotic, anti-proliferative, anti-inflammatory and anti-thrombotic action.The Corin gene of 244109pb has many variants that produce an inefficient protein with the corollary of the appearance of metabolic and cardiovascular pathologies in the first rank of which the HTA, the cardiac insufficiency and the renal insufficiency .Recently, a double polymorphism of the Corin gene consisting of 2 SNPs (single nucleotide polymorphisms) on the same allele of the Corin gene (I555\u002FP568) has been reported. This allele is present in the heterozygous state in 12% of African Americans but is extremely rare in Americans of European descent (\\\u003C0.5%).This double polymorphism (I555\u002FP568) has been shown to be responsible for an approximately 70% reduction in the ability of the mutated Corin protein to convert proANP or proBNP to the active form. In addition, the I555(P568) allele of Corin protein is associated with an increased risk of hypertension and concentric cardiac hypertrophy The corin allele (I555\u002FP568) is reported to be associated with poorer response to validated heart failure therapy and a higher risk of death or hospitalization for heart failure .\n\nIn Guadeloupe, where the population is predominantly of African descent.Cardiovascular disease is the leading cause of mortality.The prevalence of hypertension is 39% and more than 50% after 50 years of age . It has increased by 10% in 10 years in Guadeloupe. In France, where the prevalence of hypertension is 31%, it has increased by only 5% over the same period.\n\nHeart failure is the main cause of admission to the cardiological emergency room of the University Hospital (49%) with a mortality of 37% at 6 months. Hypertension is the first risk factor associated with heart failure (80%).To date, there are no studies on corin gene polymorphisms in Guadeloupe. Following the example of work already done in the African American population, we propose to study the role of the double polymorphism (I555\u002FP568) in the determinism of hypertension in the population of African descent in Guadeloupe.",[120],"High Blood Pressure",[122,123,124,125,126],"double polymorphisme","Corin","natriuretic peptide","biomarker","Afro Caribbean",{"date":100,"type":35},{"date":129,"type":35},"2025-01-16",{"date":131,"type":20},"2026-08",{"name":41,"class":42},2,{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":138,"acronym":139,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":141,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":143,"conditions":144,"keywords":147,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":43},"100615426","prevalence-of-helicobacter-pylori-on-patients-with-chronic-inflammatory-bowel-disease-ibd-at-the-chu-of-guadeloupe-100615426","NCT07292454","Prevalence of Helicobacter Pylori on Patients With Chronic Inflammatory Bowel Disease (IBD) at the CHU of Guadeloupe","HP-MICI","Inclusion Criteria:\n\nPatients over 18 years old Patients with IBD from the CHU of Guadeloupe Patients benefiting from an investigation of H. pylori infection through gastric biopsies and\u002For serology at the time of diagnosis of IBD Patients affiliated to the French social security system Free informed and written consent signed by the participant and the investigator (at the latest on the day of inclusion and before any examination required by the research)\n\nExclusion Criteria:\n\nPatients of less than18 years Patients having not given their writing informed consent",{"count":142,"type":20},100,"Clinical and experimental data suggest that dysbiosis may play a pivotal role in the pathogenesis of intestinal bowel disease (IBD). However, to the best of our knowledge, the composition of gastric and of intestinal microbiome has never been investigated in a population with IBD according to the presence\u002Fabsence of Helicobacter pylori (H. pylori) in the stomach.",[145,146],"HELICOBACTER PYLORI INFECTIONS","Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis)",[148,149,145,150],"intestinal microbioma","gastric microbioma","Inflammatory Bowel Disease","2025-12-05",{"date":153,"type":35},"2025-12-18",{"date":155,"type":20},"2025-12-15",{"date":157,"type":20},"2026-12-15",{"name":41,"class":42},{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":163,"acronym":164,"eligibilityCriteria":165,"healthyVolunteers":11,"sex":16,"minAge":166,"maxAge":4,"enrollmentInfo":167,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":169,"conditions":170,"keywords":172,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":43},"100613393","severity-factors-of-dermatomyositis-in-the-caribbean-population---dm-antilles-100613393","NCT07265999","Severity Factors of Dermatomyositis in the Caribbean Population - DM-ANTILLES","DM-ANTILLES","Inclusion Criteria:\n\n* Patient with a diagnosis of dermatomyositis according to the 2003 ENMC criteria\n* Patient with parents or grandparents originating from the Caribbean arc\n* Patient aged 16 years or older\n* Patient residing in Guadeloupe\n* Patient (or legal representative) who has received information about the study and has signed the informed consent form\n* Patient affiliated with a social security scheme\n\nExclusion Criteria:\n\n* Patient who started treatment with intravenous immunoglobulins, corticosteroids, or immunosuppressants within the month prior to the diagnosis of dermatomyositis\n* Patient under legal protection (guardianship or trusteeship) or deprived of liberty","16 Years",{"count":168,"type":20},10,"Dermatomyositis is a rare chronic autoimmune and inflammatory disease that affects the skin and striated muscles. Its prognosis is linked to visceral involvement (lungs, heart, and oropharyngeal region) and to the possible presence of associated cancer. The implementation of the research will allow identification of incident cases of dermatomyositis in Guadeloupe and the characterization of the disease in the overseas population, in the absence of data in the literature.",[171],"Dermatomyositis",[171],"2025-12-03",{"date":151,"type":35},{"date":176,"type":35},"2021-07-16",{"date":178,"type":20},"2029-07-16",{"name":41,"class":42},{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":184,"acronym":185,"eligibilityCriteria":186,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":187,"targetDuration":4,"studyType":21,"phases":189,"briefSummary":190,"conditions":191,"keywords":195,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":199,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":106},"100613392","comparison-between-a-robotic-tele-echo-cardiography-technique-and-a-standard-echocardiography-in-the-management-of-heart-failure-in-the-guadeloupe-archipelago-between-the-university-hospital-of-guadeloupe-and-the-marie-galante-hospital-100613392","NCT07265986","Comparison Between a Robotic Tele-echo-cardiography Technique and a Standard Echocardiography in the Management of Heart Failure in the Guadeloupe Archipelago Between the University Hospital of Guadeloupe and the Marie-Galante Hospital","TER de blueS","Inclusion Criteria:\n\n* Age ≥18 years\n\n  * Free, informed and written consent signed by the participant and the investigator\n  * Person affiliated or benefiting from a social security scheme.\n  * Patient meeting at least one of the following criteria:\n* Systematic cardiovascular check-up or asymptomatic patient with cardiovascular risk factor (hypertension, diabetes, obesity, tobacco, alcohol)\n* Clinical suspicion of heart disease and\u002For chronic heart failure with stability of at least one week.\n\n  * Family history of heart disease and\u002For sudden death\n\nExclusion Criteria:\n\n* Patient requiring urgent cardiological management with transfer to the University Hospital\n\n  * Acute unstable heart failure, admission to CH Marie-Galante less than 5 days (less than one week)\n  * Pregnant women",{"count":188,"type":20},50,[23],"The TERdeblue-S study is a feasibility study of robotic remote echocardiography, not only in terms of technology but also in terms of its integration into a telemedicine system to improve access to the heart failure management system in the Guadeloupe archipelago. The main objective of this study is to study the agreement of the measurement of the left ventricular ejection fraction (FejVG) between in situ echocardiography (EIS) and two-dimensional remote echocardiography (TER) (distance and volumes).",[192,193,194],"Heart Failure","Remote Consultation, Teleconsultation","Echocardiography, Doppler",[196,197,198],"heart failure","remote echocardiography doppler","telemedicine",{"date":151,"type":35},{"date":201,"type":35},"2025-11-30",{"date":203,"type":20},"2026-09-08",{"name":41,"class":42},{"id":206,"slug":207,"hasResults":11,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":211,"eligibilityCriteria":212,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":213,"targetDuration":4,"studyType":21,"phases":215,"briefSummary":216,"conditions":217,"keywords":220,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":225,"startDateStruct":226,"completionDateStruct":227,"leadSponsor":229,"locationsCount":43},"100613421","validation-of-a-voice-management-program-in-schizophrenia-vvoice-maps-100613421","NCT07266376","Validation of a VOICE MAnagement Program in Schizophrenia VVoice MAPS","Validation of a VOICE MAnagement Program in Schizophrenia","PROGEVs","Inclusion Criteria\n\nConsenting patients over 18 years of age will be enrolled in the study if they meet all of the following criteria:\n\n* Diagnosis: Fulfill DSM-5 criteria for schizophrenia or schizoaffective disorder.\n* Resistant AVHs: Present treatment-resistant auditory verbal hallucinations (AVHs), defined as the persistence of daily hallucinations without remission despite adequate antipsychotic medication for at least 3 months.\n* Motivation: Express a request for relief from voices.\n* Treatment Setting: Are outpatients being treated in psychiatric departments at the Public Mental Health Institution of Guadeloupe or the University Hospital Center of Nîmes.\n* Severity: Have a score of greater than 9 on the Psychotic Symptom Rating Scale - Auditory Hallucinations subscale (PSYRATS-AH).\n\nExclusion Criteria :\n\nPatients will be excluded from the study if they meet any of the following criteria:\n\n* Participation in another study: Currently taking part in another clinical trial or within the exclusion period of another study.\n* Consent refusal: Refuse to sign the written informed consent.\n* Inability to provide informed consent: Failure or impossibility to provide the patient with sufficient information to allow an informed decision.\n* Severe substance abuse: Presence of severe substance use disorder.\n* Acute somatic decompensation: Experiencing an acute medical condition that may compromise participation in the study.",{"count":214,"type":20},116,[23],"Approximately 25-50% of patients with schizophrenia experience treatment-resistant Auditory Verbal Hallucinations (AVHs), which contribute to the development of associated psychopathological disorders (e.g., anxiety, depression, suicidal ideation). Various validated psychotherapeutic strategies and tools for managing treatment-resistant AVHs have been combined into an integrative therapeutic program. The main objective of this study is to evaluate the efficacy of this program in reducing the frequency and intensity of AVHs, as well as its impact on comorbid psychopathology (e.g., depression, anxiety, self-esteem, substance use) in patients with schizophrenia or schizoaffective disorder who experience treatment-resistant AVHs.",[218,219],"Mental Disorder","Schizophrenia Diagnosis",[221,222,223,224],"Schizophrenia","Auditory Verbal Hallucinations","Groupal Intervention","Integrative Approach",{"date":151,"type":35},{"date":98,"type":20},{"date":228,"type":20},"2027-01-05",{"name":41,"class":42},{"id":231,"slug":232,"hasResults":11,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":236,"eligibilityCriteria":237,"healthyVolunteers":11,"sex":16,"minAge":238,"maxAge":4,"enrollmentInfo":239,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":240,"conditions":241,"keywords":244,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":255,"locationsCount":43},"100612243","acute-infectious-encephalitis-and-myelitis-in-guadeloupe-by-new-generation-sequencing-100612243","NCT07251049","Acute Infectious Encephalitis and Myelitis in Guadeloupe by New Generation Sequencing","Acute Infectious Encephalitis and Myelitis in Guadeloupe by New Generation Sequencing Acute Infectious Encephalitis and Myelitis in Guadeloupe by New Generation Sequencing","EMAI-NGS","Inclusion Criteria:\n\n* We selected the following eligibility criteria for patients with acute encephalitis:\n\n  * Patient of at least 28 days of life\n  * With acute onset of symptoms for more than 24 hours\n  * A major criterion among the following:\n* a disorder of consciousness or alertness\n* memory disorder\n* lethargy\n* modification of personal or behavioral disorder, irritability\n* confusion, disorientation in time or space\n\n  \\- At least two of the following minor criteria:\n* temperature above 38 ° C\n* new onset focal neurological deficit\n* epileptic crisis\n* biological abnormality of CSF (≥ 5 Leukocytes \u002F mm3, protein ≥ 0.40 g \u002F L)\n* partial or general epileptic seizure (s) not attributable to pre-existing epileptic disease and \u002F or a recent focal neurological symptom\n* brain imaging suggestive of encephalitis, with EEG abnormalities suggestive of encephalitis\n\n  * And absence of alternative diagnosis (intoxication, metabolic encephalopathy)\n  * Persons affiliated or benefiting from a social security scheme;\n  * Having given free, informed, written and signed consent by the patient or his legal representative (no later than the day of inclusion and prior to any review required by the research);\n* Eligibility criteria for Acute Transverse Myelitis Patients:\n\n  * Patient of at least 28 days of life\n  * Acute onset of symptoms for more than 24 hours\n  * Medullary focal abnormality, responsible for motor, sensory or autonomic symptoms\n  * contrast enhancement on bone marrow MRI and \u002F or abnormal CSF (≥ 5GB \u002F mm3, protein uptake ≥ 0.40 g \u002F L)\n  * Evolution between nadir and maximum symptoms, less than 4 weeks\n  * Persons affiliated or benefiting from a social security scheme;\n  * Having given free, informed, written and signed consent by the patient or his legal representative (no later than the day of inclusion and prior to any review required by the research);\n\nExclusion Criteria:\n\n* Primary vasculitis of the central nervous system or a documented specific impairment in an autoimmune condition\n* Cerebral thrombophlebitis if not associated with encephalitis\n* Meningitis without clinical or paraclinical argument for cerebral parenchymal involvement\n* Pyogenic abscess\n* Cerebral or spinal abscess\n* Tumoral or hematological pathology of the central nervous system\n* Toxic or metabolic encephalopathy\n* Transverse myelitis with vascular or traumatic origin\n* Known chronic infection with HTLV virus","28 Days",{"count":142,"type":20},": Encephalitis or myelitis is defined as the inflammatory or infectious involvement of the cerebral parenchyma or spinal cord. When an infectious origin is suspected, the germ is not always identified. Next-generation sequencing could be used to correct an etiological diagnosis of these severe conditions in Guadeloupe. The rate of cases for which the infectious agent is not identified encourages continued diagnostic efforts, with the objective of identifying new pathogens or emerging pathogens, some of which may be more specific in the tropics.",[242,243],"Acute Encephalitis","Acute Myelitis",[245,246,247,248],"Acute Infectious encephalitis","myelitis","next generation sequencing","French West Indies","2025-11-18",{"date":102,"type":35},{"date":252,"type":35},"2023-11-16",{"date":254,"type":20},"2028-11-16",{"name":41,"class":42},{"id":257,"slug":258,"hasResults":11,"nctId":259,"briefTitle":260,"officialTitle":260,"acronym":261,"eligibilityCriteria":262,"healthyVolunteers":114,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":263,"targetDuration":4,"studyType":21,"phases":265,"briefSummary":266,"conditions":267,"keywords":269,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":273,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":278,"locationsCount":43},"100612242","serum-chordecone-concentration-in-guadeloupean-population-impact-of-a-multidisciplinary-support-program-on-the-reduction-of-the-contamination-level-100612242","NCT07251036","Serum Chordecone Concentration in Guadeloupean Population: Impact of a Multidisciplinary Support Program on the Reduction of the Contamination Level.","ChlorGua","* All subject overs 18 years of age residing in Guadeloupe invited to participate to the program by the Regional Health Agency or subjects who requested a test from their doctor in the framework of the ministerial measure.\n* Subjects who have read the information note and signed the consent to participate in the study\n* Subjects with social security coverage\n\nExclusion Criteria:\n\n* Refusal to participate\n* Person not affiliated with a social security scheme\n* Person under legal protection (safeguard of justice, guardianship, curatorship, etc.",{"count":264,"type":20},3000,[23],"The French West Indies (Guadeloupe, Martinique) are characterized by a major use of pesticides in bananas plantation from the 1950s. These crops used organochlorine insecticides and especially chlordecone (CLD) from 1972 to 1993. The lack of biotic and abiotic degradation of CLD led to persistent soil pollution, contamination of surface and deep waters, of numerous plant and animal, and of the population. The extent and persistence of CLD contamination over time is a major issue for these territories. An internal reference value (0.4μg\u002Fl) was recently determined. Although useful for a population approach, it must be used with caution for the interpretation of an individual result. In response to the strong social demand expressed by the population for access to free chlordecone blood tests, a screening program for blood chlordecone test was authorized by the 2019 French Finance Act.",[268],"Chlordecone Level",[270,271,272,28],"risk factors","pesticides","Guadeloupe",{"date":102,"type":35},{"date":275,"type":35},"2022-06-26",{"date":277,"type":20},"2028-06",{"name":41,"class":42},{"id":280,"slug":281,"hasResults":11,"nctId":282,"briefTitle":283,"officialTitle":283,"acronym":284,"eligibilityCriteria":285,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":286,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":287,"conditions":288,"keywords":291,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":294,"lastUpdatePostDateStruct":295,"startDateStruct":296,"completionDateStruct":298,"leadSponsor":300,"locationsCount":133},"100610889","prevalence-of-h-pylori-in-stomach-cancers-in-the-west-indies-100610889","NCT07233447","Prevalence of H. Pylori in Stomach Cancers in the West Indies","PyloCaGe","Inclusion Criteria:\n\n* Patient over 18 years of age residing in Guadeloupe for more than 6 months and with a primary diagnosis of gastric cancer\n* Patient having read the information note and having signed the consent to participate in the study\n* Patient with social security coverage.\n\nExclusion Criteria:\n\n* Refusal to participate.\n* Patient who could not answer the questionnaires\n* Patient not affiliated to a social security scheme\n* Patient under legal protection (judicial safeguard, guardianship, curatorship, etc.)\n* Pregnant or breastfeeding woman\n* Subject participating in another research study that includes an exclusion period still ongoing at the time of pre-inclusion",{"count":142,"type":20},"The incidence and mortality of stomach cancer are higher in the French West Indies than in mainland France. The prevalence of H. pylori infection associated with this cancer remains unknown in these populations. The main objective of the study is to estimate the prevalence of H. Pylori detected by immunohistochemistry in patients newly diagnosed with cancer.",[289,290],"Oncology Epidemiology","Risk Factors",[292,272,293],"H. Pylori","stomach cancer","2025-11-14",{"date":249,"type":35},{"date":297,"type":35},"2025-02-24",{"date":299,"type":20},"2027-02-24",{"name":41,"class":42},{"id":302,"slug":303,"hasResults":11,"nctId":304,"briefTitle":305,"officialTitle":306,"acronym":307,"eligibilityCriteria":308,"healthyVolunteers":11,"sex":309,"minAge":17,"maxAge":310,"enrollmentInfo":311,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":313,"conditions":314,"keywords":316,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":294,"lastUpdatePostDateStruct":323,"startDateStruct":325,"completionDateStruct":327,"leadSponsor":329,"locationsCount":43},"100610740","chlordecone-exposure-and-female-fertility-100610740","NCT07231510","Chlordecone Exposure and Female Fertility","KARU-FERTIL: Chlordecone Exposure and Female Fertility","KARU-FERTIL","Inclusion Criteria:\n\n* Women aged from 18 to 39 years\n* Consulting for couple infertility at the Centre Caribéen de Médecine de la Reproduction (CCMR, Caribbean Center for Reproductive Medicine) of the University Hospital of Guadeloupe\n* Free, informed and written consent\n\nExclusion Criteria:\n\n* Women aged from 18 to 39 years\n* Consulting for couple infertility at the Centre Caribéen de Médecine de la Reproduction (CCMR, Caribbean Center for Reproductive Medicine) of the University Hospital of Guadeloupe\n* Free, informed and written consent","FEMALE","39 Years",{"count":312,"type":20},634,"Chlordecone is an organochlorine pesticide used in the French West Indies (FWI) from 1972 to 1993 to control the banana root borer. Due to its very long persistence the population continues to be exposed to this chemical through their food consumptions. Although, chlordecone have been associated in animal study impairment of ovarian reserve, to date, no study has been published concerning the link between chlordecone exposure and female fertility. The main objective of this project is to study the association between chlordecone exposure and anti-mullerian hormone (AMH) in women consulting for couple infertility in Guadeloupe.",[315],"Infertility Female",[317,318,319,320,321,28,322],"polycystic ovarian syndrome","endometriosis","female infertility,","ovarian reserve","environmental exposures","kepone",{"date":324,"type":35},"2025-11-17",{"date":326,"type":35},"2024-01-26",{"date":328,"type":20},"2028-01-26",{"name":41,"class":42},{"id":331,"slug":332,"hasResults":11,"nctId":333,"briefTitle":334,"officialTitle":335,"acronym":336,"eligibilityCriteria":337,"healthyVolunteers":114,"sex":16,"minAge":17,"maxAge":338,"enrollmentInfo":339,"targetDuration":4,"studyType":21,"phases":341,"briefSummary":342,"conditions":343,"keywords":345,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":294,"lastUpdatePostDateStruct":351,"startDateStruct":352,"completionDateStruct":354,"leadSponsor":356,"locationsCount":43},"100610888","screening-for-type-2-diabetes-by-oral-glucose-tolerance-test-in-the-population-groups-not-diagnosed-by-fasting-blood-glucose-in-guadeloupe-100610888","NCT07233434","Screening for Type 2 Diabetes by Oral Glucose Tolerance Test in the Population Groups Not Diagnosed by Fasting Blood Glucose in Guadeloupe","Screening for Type 2 Diabetes by Oral Glucose Tolerance Test in the Population Groups Not Diagnosed by Fasting Blood Glucose in Guadeloupe: a Pilot Study","DIADEG","o Inclusion criteria : Adult subject (over 18 years and under 65 years old) Subjects of African or Indian origin and self-declared Normal FBG levels (110mg\u002FdL) HbA1c levels between 5.7 and 6.4% One or more of the following factors: BMI \\> 25 kg\u002Fm2, family history of T2DM in the 1st and 2nd familial degree, hypertension, dyslipidemia.\n\nAffiliation to the national social health system or equivalent Informed and written consent signed by the patient and the investigator (at the latest on the day of inclusion and before the completion of any research related exam)\n\no Exclusion criteria : Pregnant or lactating woman Women with a history of gestational diabetes Polycystic ovary syndrome Endocrine, hepatic or renal diseases affecting glycemic control Treatment that affect the metabolism of glucose or insulin Refusal to participate Subjects without adequate or impaired decisional abilities for consent to research and placed under guardianship, curatorship or safeguard of justice, person participating in another research including an exclusion period still in progress, severely impaired physical and \u002F or psychological health, which, according to the investigator, may affect the compliance of the study participant","65 Years",{"count":340,"type":20},120,[23],"In France, only the fasting blood glucose (FBG) measurement is recommended for diabetes screening. Ethnic heterogeneity and genetic polymorphisms specific to the Afro-Caribbean and Indo-Caribbean population in Guadeloupe justify the interest to early screen type 2 diabetes mellitus (T2DM). Our main objective is to estimate the prevalence of T2DM defined by oral glucose tolerance (OGTT) in subjects with risk factors for T2DM and not diagnosed with the FBG.",[344],"Non-Diabetic",[346,347,348,349,350],"oral glucose tolerance","type 2 diabetes mellitus","Fasting blood glucose","HbA1c","screening",{"date":249,"type":35},{"date":353,"type":35},"2021-02-02",{"date":355,"type":20},"2028-08-02",{"name":41,"class":42},{"id":358,"slug":359,"hasResults":11,"nctId":360,"briefTitle":361,"officialTitle":361,"acronym":362,"eligibilityCriteria":363,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":364,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":366,"conditions":367,"keywords":371,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":294,"lastUpdatePostDateStruct":374,"startDateStruct":375,"completionDateStruct":377,"leadSponsor":379,"locationsCount":43},"100610695","study-of-the-rate-of-progression-of-cerebral-ischemia-in-afro-caribbeans-100610695","NCT07230925","Study of the Rate of Progression of Cerebral Ischemia in Afro-Caribbeans","VESPERALS","* inclusion criteria:\n\n  * Patients aged 18 and over, admitted for IC due to LVO verified by medical imaging and hospitalized in neurology.\n  * Patients residing in Guadeloupe\n  * Afro-Caribbean patients: of African ancestry.\n  * Emergency inclusion, with exemption from obtaining consent due to the immediate life-threatening emergency situation of the patient (Article L1122-1-3 of the French Public Health Code); as soon as possible, consent to continue will be sought from the patient or, if applicable, from a relative or a trusted person.\n  * Patients affiliated to a social security scheme or equivalent\n* exclusion criteria:\n\n  * Patients under 18 years old\n  * Non-resident patients in Guadeloupe\n  * Protected persons (articles L1121-5, L1121-6 and L121-8 of the Public Health Code): pregnant or breastfeeding women, persons deprived of their liberty, under guardianship or curatorship)\n  * Withdrawal of consent during the study\n  * Patients not affiliated to a social security or equivalent scheme",{"count":365,"type":20},135,"To compare the progression of cerebral ischemia from HF in Afro-Caribbean patients admitted to the CHUG to that of patients from Nantes included in the national ETIS registry.",[368,369,370],"Ischemic Stroke","Cerebral Ischemia","Endovascular Treatments",[372,373],"Cerebrovascular accident","Cerebral Blood Flow",{"date":324,"type":35},{"date":376,"type":20},"2026-01",{"date":378,"type":20},"2028-01",{"name":41,"class":42},{"id":381,"slug":382,"hasResults":11,"nctId":383,"briefTitle":384,"officialTitle":384,"acronym":385,"eligibilityCriteria":386,"healthyVolunteers":11,"sex":16,"minAge":166,"maxAge":387,"enrollmentInfo":388,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":390,"conditions":391,"keywords":394,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":294,"lastUpdatePostDateStruct":400,"startDateStruct":401,"completionDateStruct":403,"leadSponsor":405,"locationsCount":43},"100566321","exposure-to-organochlorine-pollutants-and-impact-on-development-in-the-peripubertal-age-in-guadeloupe-100566321","NCT06653660","Exposure to Organochlorine Pollutants and Impact on Development in the Peripubertal Age in Guadeloupe","TIMOUNPUBERTY","Inclusion Criteria:\n\n* Be born to a mother whose pregnancy was included in the Timoun cohort (2004 - 2007) and whose parents agreed to be contacted later.\n* Residing in Guadeloupe at the peripubertal age\n* Affiliation to a social security scheme\n* Agreement to participate in the study and informed consent signed by the minor\n* Study participation agreement and informed consent signed by the parents\n\nExclusion Criteria:\n\n* Refusal to participate in the research","22 Years",{"count":389,"type":20},650,"In the context of environmental pollution of the French West Indies by chlordecone and questions about health consequences, monitoring at the peripubertal age of children born alive in the TIMOUN cohort is justified in several respects: - existence of an already established mother-child cohort whose live-born children will reach peripubertal ages during the period 2020-2022; - opportunity to verify hypotheses put forward on the basis of toxicological data acquired in laboratory animals and the hormonal characteristics of chlordecone (endocrine disruptor); - strong societal demand for such research to be carried out because of concerns about the sensitivity of children and adolescents to the effects of environmental xenobiotics, in particular on sexual development and the age of puberty; - recommendation of the Scientific Council Chlordecone Inserm - InVS; specific action of the National Plan Chlordecone IV.",[392,393],"Prenatal Exposure","Postnatal Exposure",[392,393,395,396,397,398,399,272,248],"Chlordecone","Persistent Organic Pollutants","Endocrine disruptors","Puberty","Development",{"date":324,"type":35},{"date":402,"type":35},"2022-12-19",{"date":404,"type":20},"2026-12-19",{"name":41,"class":42},{"id":407,"slug":408,"hasResults":11,"nctId":409,"briefTitle":410,"officialTitle":410,"acronym":411,"eligibilityCriteria":412,"healthyVolunteers":11,"sex":413,"minAge":17,"maxAge":4,"enrollmentInfo":414,"targetDuration":4,"studyType":21,"phases":415,"briefSummary":416,"conditions":417,"keywords":4,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":294,"lastUpdatePostDateStruct":422,"startDateStruct":423,"completionDateStruct":425,"leadSponsor":427,"locationsCount":133},"100519636","clinical-genetic-and-environmental-determinants-of-prostate-cancer-progression-100519636","NCT06046131","Clinical, Genetic and Environmental Determinants of Prostate Cancer Progression.","KP-CARAIBES","Inclusion Criteria:\n\nInclusion criteria:\n\nAdult patients with incident case of prostate cancer Patient consulting the University Hospital of Guadeloupe or the University Hospital of Rennes Patient who resides in the departments of Guadeloupe or Martinique or the community of Saint-Martin or in Britany Patient affiliated or beneficiary of the social security signed consent\n\nExclusion Criteria:\n\nPhysical or mental health judjed by the investigator as precluding participation in the research Protected adults (guardianship, curatorship, safeguard of justice).","MALE",{"count":264,"type":20},[23],"The course and progression of prostate cancer is highly variable, depending on the individual characteristics, the aggressiveness of the disease at the time of diagnosis as well as the ethno-geographic origins of the individuals. The general objective of the project is to identify the clinical, genetic and environmental determinants (risk factors) of the evolution, progression and complications of the disease according to the treatment options. Identifying modifiable and non-modifiable prognostic determinants of disease progression is a major challenge. This knowledge will help guide treatment choices but also, especially in high-risk populations (high incidence of disease) to better tailor prevention policies and possibly screening .",[418,419,420,421],"Prostatic Neoplasm","Adenocarcinoma","Neoplasm Recurrence","Neoplasm Metastasis",{"date":324,"type":35},{"date":424,"type":35},"2023-02-28",{"date":426,"type":20},"2039-02-28",{"name":41,"class":42},{"id":429,"slug":430,"hasResults":11,"nctId":431,"briefTitle":432,"officialTitle":433,"acronym":434,"eligibilityCriteria":435,"healthyVolunteers":114,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":436,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":438,"conditions":439,"keywords":441,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":445,"lastUpdatePostDateStruct":446,"startDateStruct":448,"completionDateStruct":450,"leadSponsor":452,"locationsCount":43},"100596056","study-of-infrared-thermography-in-diabetic-foot-in-guadeloupe-100596056","NCT07040488","Study of Infrared Thermography in Diabetic Foot in Guadeloupe","Study of Infrared Thermography in Diabetic Foot in Guadeloupe (ETPDG)","ETPDG","Inclusion Criteria for Control Group\n\n* Adult patients\n* Patients of Afro-Caribbean origin\n* Volunteer patients free from pathology\n* Person affiliated to or beneficiary of a social security scheme.\n* Person who has agreed to sign a consent to participate in the study\n\nInclusion Criteria for diabetic patients:\n\n* Adult patients\n* Patients of Afro-Caribbean origin\n* Type 1 or type 2 diabetic patients with and without diabetic foot ulceration\n* Person affiliated to or beneficiary of a social security system.\n* Person who has agreed to sign a consent to participate in the study\n\nExclusion Criteria :\n\n* \\- Minors\n* patient with an active fracture or a history of fracture\n* a history of legs surgery\n* History of amputation\n* Bilateral diabetic ulceration\n* neurological disease (Parkinson, stroke, etc.)\n* pregnancy\n* Foot mycosis\n* refusal of consent",{"count":437,"type":20},150,"It is hypothesized that thermal imaging differs between diabetic and non-diabetic individuals in Guadeloupe. Infrared thermography is also suggested as a useful tool for studying diabetic foot ulceration. The main objective is to compare the temperatures of four areas of the plantar surface of the foot among non-diabetic individuals, diabetic individuals, and diabetic individuals with foot ulceration.",[440],"Diabetic Foot Infection",[442,443,444],"Infrared thermography","diabetic foot","infection","2025-06-18",{"date":447,"type":35},"2025-06-27",{"date":449,"type":35},"2024-09-27",{"date":451,"type":20},"2026-03-27",{"name":41,"class":42},{"id":454,"slug":455,"hasResults":11,"nctId":456,"briefTitle":457,"officialTitle":457,"acronym":458,"eligibilityCriteria":459,"healthyVolunteers":114,"sex":16,"minAge":17,"maxAge":338,"enrollmentInfo":460,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":462,"conditions":463,"keywords":465,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":467,"lastUpdatePostDateStruct":468,"startDateStruct":470,"completionDateStruct":472,"leadSponsor":474,"locationsCount":133},"100592818","ethnic-specificities-of-s100b-protein-blood-level-in-guadeloupe-cross-sectional-study-in-healthy-subjects-100592818","NCT06998381","Ethnic Specificities of S100B Protein Blood Level in Guadeloupe: Cross-sectional Study in Healthy Subjects","PS100B-G","Inclusion Criteria :\n\n* Hospital staff of the University Hospital of Guadeloupe or the Hospital of Basse-Terre\n* Age between 18 and 65 years\n* Individuals willing to specify their ethnic origin and skin phototype\n* Individuals affiliated with or beneficiaries of a social security scheme\n* Informed individuals who have given their voluntary, informed, and written consent\n\nExclusion Criteria :\n\n* Individuals on anticoagulant therapy\n* Individuals with a personal history of neurological disease\n* Individuals with a personal history of melanoma\n* Refusal to participate\n* Individuals under guardianship, curatorship, or legal protection",{"count":461,"type":20},200,"Numerous studies have demonstrated the significant contribution of S100B blood level measurement in the management of minor to moderate traumatic brain injuries, notably by reducing the number of cranial computed tomography (CT) scans by at least one-third. However, physiological blood concentrations of the S100B protein may be higher in individuals with a Black phenotype compared to those with Asian or, in particular, Caucasian phenotypes. Assessing S100B protein levels in healthy individuals will help confirm the variability of its physiological concentration according to skin phenotype.",[464],"s100b",[466],"S100B Protein","2025-05-30",{"date":469,"type":35},"2025-05-31",{"date":471,"type":35},"2023-02-01",{"date":473,"type":20},"2025-08-01",{"name":41,"class":42},{"id":476,"slug":477,"hasResults":11,"nctId":478,"briefTitle":479,"officialTitle":479,"acronym":480,"eligibilityCriteria":481,"healthyVolunteers":114,"sex":16,"minAge":482,"maxAge":483,"enrollmentInfo":484,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":486,"conditions":487,"keywords":490,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":467,"lastUpdatePostDateStruct":494,"startDateStruct":496,"completionDateStruct":498,"leadSponsor":500,"locationsCount":43},"100593000","molecular-and-cellular-basis-of-severe-forms-of-dengue-in-sickle-cell-patients-100593000","NCT07000747","Molecular and Cellular Basis of Severe Forms of Dengue in Sickle Cell Patients","DREPADENGUE","Inclusion Criteria:\n\n* patients with SS or SC SCD or controls with hemoglobin AA\n* diagnosis of SCD performed by electrophoresis or HPLC in a reference laboratory for hemoglobinopathies\n* patients older than 6 years and younger than 25 at inclusion\n* clinically in a steady state at inclusion (without complication during the last month and without transfusion in the three last months)\n* patients followed up for SCD at the sickle cell center of Guadeloupe (University hospital of Guadeloupe, Pointe-à-Pitre)\n* patients or legal representatives of minors who will provide written informed consent in accordance with the Declaration of Helsinki\n* patients affiliated to national social security\n* the control group (AA subjects) will be recruited among volunteers recruited by posters\n\nExclusion Criteria:\n\n* patients with SS or SC SCD or controls with hemoglobin AA\n* diagnosis of SCD performed by electrophoresis or HPLC in a reference laboratory for hemoglobinopathies\n* patients older than 6 years and younger than 25 at inclusion\n* clinically in a steady state at inclusion (without complication during the last month and without transfusion in the three last months)\n* patients followed up for SCD at the sickle cell center of Guadeloupe (University hospital of Guadeloupe, Pointe-à-Pitre)\n* patients or legal representatives of minors who will provide written informed consent in accordance with the Declaration of Helsinki\n* patients affiliated to national social security\n* the control group (AA subjects) will be recruited among volunteers recruited by posters","6 Years","25 Years",{"count":485,"type":20},130,"Dengue virus (DENV) belongs to the genus of Flavivirus transmitted by the mosquito Aedes aegypti and is responsible for an infectious disease associated with different forms and severities such as dengue hemorrhagic fever or shock syndrome. Several recent reports have shown that sickle cell patients exhibited an increased risk of developing severe forms of dengue episodes compared to non-sickle cell subjects. Furthermore, among major sickle cell syndromes, these studies suggest that SC patients are at the highest risk of death during these infectious episodes although this sickle cell syndrome is generally associated with a more moderate expression of sickle cell disease. However, the mechanisms involved remain unknown to date.\n\nThe aim of the present study is to identify the molecular and cellular basis of this increased severity of dengue in SC patients. We hypothesize an exacerbation during DENV infection of the inflammatory response in SC patients compared to SS patients.",[488,489],"Dengue (Virus); Fever, Sandfly","Sickle Cell Disease",[491,492,493],"extracellular vesicles","blood immune cells","Dengue virus",{"date":495,"type":35},"2025-06-03",{"date":497,"type":35},"2024-06-24",{"date":499,"type":20},"2026-06-24",{"name":41,"class":42},{"id":502,"slug":503,"hasResults":11,"nctId":504,"briefTitle":505,"officialTitle":505,"acronym":506,"eligibilityCriteria":507,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":508,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":510,"conditions":511,"keywords":514,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":517,"lastUpdatePostDateStruct":518,"startDateStruct":519,"completionDateStruct":521,"leadSponsor":523,"locationsCount":43},"100593034","impact-of-regional-anesthesia-on-inflammatory-mechanisms-during-vaso-occlusive-crisis-in-sickle-cell-patients-100593034","NCT07001189","Impact of Regional Anesthesia on Inflammatory Mechanisms During Vaso-occlusive Crisis in Sickle Cell Patients","ALRCVO-MP","Inclusion Criteria:\n\n* patients adult \\>18 years\n* patients with vaso-occlusive crisis\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women\n* Blood transfusion within the last 3 months\n* Lack of affiliation with the French social security system\n* Protected individuals",{"count":509,"type":20},34,"Sickle cell disease is a chronic disease characterized by multiple vaso-occlusive complications. The basic treatment for patients with a vaso-occlusive crisis (VOC) is based on adequate hydration, oxygen therapy and pain control. Loco Regional Anesthesia (LRA) is one of the major treatments in resuscitation anesthesia for both anesthesia and analgesia. LRA allows effective and almost immediate pain control by blocking nerve afferents in a given area. LRA could decrease the inflammatory response during crises and accelerate resolution of the crisis.",[512,489,513],"Sickle Cell","Vaso-Occlusive Crises",[515,516,513],"Loco-regional anesthesia","inflammation","2025-05-23",{"date":495,"type":35},{"date":520,"type":35},"2025-02-05",{"date":522,"type":20},"2027-02-05",{"name":41,"class":42},{"id":525,"slug":526,"hasResults":11,"nctId":527,"briefTitle":528,"officialTitle":529,"acronym":530,"eligibilityCriteria":531,"healthyVolunteers":114,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":532,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":533,"conditions":534,"keywords":536,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":517,"lastUpdatePostDateStruct":542,"startDateStruct":544,"completionDateStruct":546,"leadSponsor":548,"locationsCount":43},"100581440","megakaryocyte-heterogeneity-in-sickle-cell-disease-100581440","NCT06850337","Megakaryocyte Heterogeneity in Sickle Cell Disease","Characterization of Megakaryocytic Subpopulations and the \"Immune\" Phenotype of Platelets of the Sickle Cell Disease Patient","MegaDrep","Inclusion Criteria:\n\n* patients with SS or SC SCD\n* diagnosis of SCD performed by electrophoresis or HPLC in a reference laboratory for hemoglobinopathies\n* patients older than 18 years at inclusion\n* clinically in a steady state at inclusion (without complication in the last month and without transfusion in the three last months)\n* patient followed up for SCD at the sickle cell center of Guadeloupe (University hospital of Guadeloupe, Pointe à Pitre)\n* patients who will provide written informed consent in accordance with the Declaration of Helsinki\n* patients affiliated to national social security\n* the control group (AA subjects) will be patients older than 18 years old who come at the University hospital of Guadeloupe, (Pointe à Pitre) for hip or knee replacement and will do not suffer from chronic disease.\n\nExclusion Criteria:\n\n* patients younger than 18 years old\n* patients with hemoglobinopathy other than SS and SC SCD\n* patients with a transfusion therapy or on bleeding therapy for less than three months\n* patients no affiliated to national social security\n* pregnant or breastfeeding patients",{"count":142,"type":20},"Sickle cell disease (SCD) is characterized by chronic hemolytic anemia, painful crisis called vaso-occlusive crisis (VOC) and chronic inflammation. Activated platelets of SCD patients participated to both chronic inflammation and painful VOC. Platelets are anucleated cells from the fragmentation of megakaryocytes in bone marrow.\n\nThe main aim of this study is to characterize the distribution of the different megakaryocyte subpopulations of sickle cell disease patients SS and SC and in particular the \"immune\" megakaryocytes CD148+CD48+ and to compare it with the platelet phenotype.",[535],"Sickle Cell Disease (SCD)",[537,538,539,540,541],"sickle cell disease","immune megakaryocytes","platelets","CD48","CD148",{"date":543,"type":35},"2025-05-25",{"date":545,"type":20},"2025-07",{"date":547,"type":20},"2027-03",{"name":41,"class":42},{"id":550,"slug":551,"hasResults":11,"nctId":552,"briefTitle":553,"officialTitle":554,"acronym":555,"eligibilityCriteria":556,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":557,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":558,"conditions":559,"keywords":561,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":566,"lastUpdatePostDateStruct":567,"startDateStruct":569,"completionDateStruct":571,"leadSponsor":573,"locationsCount":133},"100574586","is-negativity-of-autoantibodies-a-marker-of-severity-in-auto-immune-hepatitis-100574586","NCT06761209","Is Negativity of Autoantibodies a Marker of Severity in Auto-immune Hepatitis?","Is Negativity of Autoantibodies a Marker of Severity in Auto-immune Hepatitis","HAI-NEG","Inclusion Criteria:\n\n* \\- Any patient over 18 years old\n* Patient followed at Hôpital Saint-Antoine or treated for HAI or in Guadeloupe within the framework of the CCRD Filfoie for an acute or chronic AIH under immunosuppressive treatment\n* Patient affiliate or beneficiary of a social security scheme\n* Free, informed and written consent signed by the patient and the investigator\n\n  o exclusion criteria: - Patient under 18 years old\n* Patient not able to give his\u002Fher consent\n* Viral hepatitis: viruses A to E, Epstein-Barr virus, cytomegalovirus and herpes simplex virus\n* Isolated primary biliary cholangitis\n* Isolated primary sclerosing cholangitis\n* Drug-induced liver injury\n* Wilson disease\n* Alcoholic hepatitis\n* Hemochromatosis\n* Sickle cell disease and heart liver\n* Non-alcoholic steato-hepatitis",{"count":142,"type":20},"Evaluate the proportion of seronegative auto-immune hepatitis and a possible relationship with the severity of the disease. Criteria of severity will be defined by corticodependance, corticoresistance and a severe form of the disease at diagnosis (cirrhosis or fulminant hepatitis). In case of predominant seronegative forms, other auto-antibodies related to this auto-immue hepatitis will be searched.",[560],"Auto-immune Hepatitis",[562,563,564,565],"autoantibodies","auto-immune hepatitis","prognosis","afrocaribbean population","2024-12-30",{"date":568,"type":35},"2025-01-07",{"date":570,"type":35},"2022-07-01",{"date":572,"type":20},"2026-12",{"name":41,"class":42},{"id":575,"slug":576,"hasResults":11,"nctId":577,"briefTitle":578,"officialTitle":578,"acronym":579,"eligibilityCriteria":580,"healthyVolunteers":114,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":581,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":583,"conditions":584,"keywords":586,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":592,"lastUpdatePostDateStruct":593,"startDateStruct":595,"completionDateStruct":597,"leadSponsor":599,"locationsCount":43},"100566638","study-and-role-of-inflammasome-in-platelet-activation-during-bacterial-andor-viral-sepsis-100566638","NCT06657781","Study and Role of Inflammasome in Platelet Activation During Bacterial And\u002For Viral Sepsis","PLAQSEPSIS","Inclusion Criteria:\n\n* For all groups: patients older than 18 years at inclusion and acceptation of participation by the patient, his relative or his legal representative (depending on the situation)\n* For groups 1, 2, 3 and 5: Patient with a confirmed sepsis (microbiological confirmation)\n* For group 4 : Patient non infected\n\nExclusion Criteria:\n\n* Refusal of participation by the patient, his relative or his legal representative (depending on the situation)\n* Patients subject to a safeguard measure of justice\n* Patients younger than 18 years at inclusion",{"count":582,"type":20},171,": Sepsis, now defined as life-threatening organ dysfunction due to a dysregulated host response to infection, is an important global health problem representing about a fifth of all global deaths. It can be associated, in some cases, with multiple organ failure and cytokine storm. The main objective of this study is to estimate and to compare the activation rate of the Nucleotide-binding domain Leucine Rich repeat containing Protein 3 (NLRP3) inflammasome in platelets between five groups of patients suffering from bacterial and\u002For viral sepsis, with different severity levels according to Sequential Organ Failure Assessment (SOFA) score to precise the platelets' implication in this cytokine storm.",[585],"Bacterial Sepsis",[587,588,589,590,591],"Sepsis","platelet","NLRP3","BTK","IL-1β","2024-10-23",{"date":594,"type":35},"2024-10-24",{"date":596,"type":35},"2022-11-30",{"date":598,"type":20},"2026-11",{"name":41,"class":42},""]